IL86650A0 - Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane - Google Patents

Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Info

Publication number
IL86650A0
IL86650A0 IL86650A IL8665088A IL86650A0 IL 86650 A0 IL86650 A0 IL 86650A0 IL 86650 A IL86650 A IL 86650A IL 8665088 A IL8665088 A IL 8665088A IL 86650 A0 IL86650 A0 IL 86650A0
Authority
IL
Israel
Prior art keywords
cells
liposomes
animal derived
membrane
derived cells
Prior art date
Application number
IL86650A
Other languages
English (en)
Original Assignee
Biophor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL86650(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biophor Corp filed Critical Biophor Corp
Priority to IL10569288A priority Critical patent/IL105692A/en
Publication of IL86650A0 publication Critical patent/IL86650A0/xx
Priority to IL105692A priority patent/IL105692A0/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
IL86650A 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane IL86650A0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL10569288A IL105692A (en) 1987-06-30 1988-06-07 Liposomes to which a membrane has been inserted angiotic protein
IL105692A IL105692A0 (en) 1987-06-30 1993-05-13 Liposomes having an antigenic protein incorporated into their membranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (1)

Publication Number Publication Date
IL86650A0 true IL86650A0 (en) 1988-11-30

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
IL86650A IL86650A0 (en) 1987-06-30 1988-06-07 Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane

Country Status (9)

Country Link
US (1) US5677176A (fr)
EP (1) EP0298280B1 (fr)
JP (2) JP2728166B2 (fr)
AT (1) ATE114476T1 (fr)
AU (2) AU1821988A (fr)
CA (1) CA1327332C (fr)
DE (1) DE3852221T2 (fr)
ES (1) ES2067457T3 (fr)
IL (1) IL86650A0 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
CA1327174C (fr) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion de proteines dans des membranes de cellules animales
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
WO1990006960A1 (fr) * 1988-12-22 1990-06-28 The Dow Chemical Company Procede ameliore de synthese de polymeres heterocycliques
WO1992006677A1 (fr) * 1990-10-19 1992-04-30 University Of Florida Enveloppes virales artificielles
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
DK0517986T3 (da) * 1991-06-14 1998-03-30 Europ Communities Transformerede erythrocytter, fremgangsmåde til fremstilling af samme og deres anvendelse i farmaceutiske præparater
WO1993018160A1 (fr) * 1992-03-11 1993-09-16 Kenneth Francis Prendergast Peptides de fusion anti-viraux
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
AU5014393A (en) * 1992-08-13 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
CA2144767A1 (fr) * 1992-09-22 1994-03-31 Guerard W. Byrne Liberation de proteines par transfert inter-membranes pour la preaccomodation d'heterotransplantations d'organes et pour d'autres applications
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
HUT76331A (en) * 1994-07-15 1997-08-28 Lepetit Spa Dinucleoside-5',5'-pyrophosphates
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
AU1734600A (en) * 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
EP1140021B1 (fr) 1998-12-23 2004-08-04 Idea Ag Formulation amelioree pour l'application topique non invasive in vivo
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
DK1031346T3 (da) 1999-01-27 2002-08-12 Idea Ag Ikke-invasiv vaccination gennem huden
EP1921451A3 (fr) * 2001-05-22 2008-05-28 Cygene, Inc. Analyses induites par complément pour procédés in vivo et in vitro
JP4428628B2 (ja) 2001-10-16 2010-03-10 コード バイオテック リミテッド 修飾細胞から製造される血清学用の感受性対照
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2282723A2 (fr) * 2008-03-26 2011-02-16 University of Oxford Liposomes ciblant le réticulum endoplasmique
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20120034156A1 (en) * 2010-08-03 2012-02-09 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
CA2777007C (fr) * 2009-10-08 2019-08-20 Otsuka Pharmaceutical Co., Ltd. Filtre de perfusion sanguine d'immunoactivation pour le traitement de tumeurs malignes
EP3071515A2 (fr) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Complexes membrane synthétique- récepteur
BR112016022814A8 (pt) 2014-04-01 2021-07-06 Rubius Therapeutics Inc composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
EP0298280A2 (fr) 1989-01-11
CA1327332C (fr) 1994-03-01
EP0298280A3 (en) 1990-05-02
JP2825804B2 (ja) 1998-11-18
DE3852221T2 (de) 1995-04-06
JPH1072368A (ja) 1998-03-17
AU1821988A (en) 1989-04-27
JPH01124382A (ja) 1989-05-17
ATE114476T1 (de) 1994-12-15
DE3852221D1 (de) 1995-01-12
ES2067457T3 (es) 1995-04-01
EP0298280B1 (fr) 1994-11-30
JP2728166B2 (ja) 1998-03-18
AU662154B2 (en) 1995-08-24
AU1942692A (en) 1992-09-24
US5677176A (en) 1997-10-14

Similar Documents

Publication Publication Date Title
IL86650A0 (en) Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
Zaremba et al. Assembly polypeptides from coated vesicles mediate reassembly of unique clathrin coats.
Masucci et al. Effect of interferon-α1 from E. coli on some cell functions
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
EP0158277A3 (fr) Préparations implantables à libération contrôlée de peptides régulateurs et procédé pour leur fabrication
DE69033700D1 (de) Il-11 aus säugetier
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
NO912825L (no) Fremgangsmaate for fremstilling av kokonjugatvaksiner omfattende im munogent protein, hiv-beslektede peptider og anioniske grupper.
EP0306219A3 (fr) Protéines et peptides du HIV pour le diagnostic, la prophylaxie et la thérapie du SIDA
IT1254360B (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
GR3007031T3 (fr)
Cerny et al. CD4+ T cells in murine acquired immunodeficiency syndrome: evidence for an intrinsic defect in the proliferative response to soluble antigen
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
DE3888290D1 (de) Mutanten des infektiösen bovinen Rhinotracheitisvirus, Vakzine die sie enthalten, Verfahren zu ihrer Herstellung und ihrer Verwendung.
EP0236977A3 (fr) Vaccins contre la diarrhée bovine virale et le choléra porcin
Gee et al. Differences between Syrian hamster strains in natural killer cell activity induced by infection with Pichinde virus
ES8303522A1 (es) Procedimiento para la mutacion doble de virus del genero herpes
IL86675A (en) Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
EP0283443A3 (en) Process for extracting membrane antigens having immunogenic properties from human neoplastic cells and products thereby obtained
Dieleman et al. Acquired Zwa antigen on Zwa negative platelets demonstrated by western blotting
Marušić et al. Involvement of Mhc loci in immune responses that are not Ir-gene-controlled
Powell et al. Identification of SIV/SMM viral proteins that induce T cell response in experimentally infected rhesus macaques and naturally infected sooty mangabeys by the cellular western blot assay
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
Hale et al. Elicitation of anti-H-2 cytotoxic T lymphocytes with antigen-modified H-2 negative stimulator cells.

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees